한글목차

• 2024년에는 GlobalData의 역학 예측에 포함된 16개국에서 300만 명 이상의 DCM 환자가 발생할 것으로 예측됩니다.
• DCM의 치료는 주로 베타차단제, ACE 억제제, ARB, MRA, SGLT2 억제제를 이용한 증상 관리에 중점을 두고 있습니다.
• 현재 파이프라인의 여러 단계에 걸쳐 34개의 분자가 DCM 치료제로 개발되고 있습니다.
• 지난 10년간 미국은 DCM 임상시험 기관 수가 가장 많은 국가로 약 110개 기관이 있었습니다.
• 지난 10년간 북미에서는 인수가 가장 많은 거래 형태였고, 중남미, 아프리카, 아시아태평양에서는 라이선싱 계약이 가장 많은 거래 형태였습니다.

세계의 확장성 심근병증(DCM) 시장에 대해 조사분석했으며, 질환 상황, 출시 약품과 파이프라인 약품의 평가, 현재와 향후 경쟁 상황등의 정보를 제공하고 있습니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약품 평가

• 주요 출시 약품
• 개요 : 작용기서별
• 개요 : 분자 유형별
• 제품 개요와 판매 예측

제5장 가격결정과 상환 평가

• 연간 치료비
• 가격결정과 상환까지의 시간

제6장 파이프라인 약품 평가

• 중기-후기 단계 파이프라인 약품
• 개요 : 개발 단계별
• 개요 : 작용기서별
• 개요 : 분자 유형별
• 약품 고유 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
• 치료 영역과 적응증 고유 PTSR과 LoA

제7장 임상시험 평가

• 과거의 개요
• 개요 : 단계별
• 개요 : 현황별
• 개요 : 단계별(진행중/계획 시험)
• 가상 컴포넌트에 의한 시험
• 지역별 시험의 개요
• 단일국/다국간 시험 : 지역별
• 스폰서 상위 20사와 내역 : 단계별
• 스폰서 상위 20사와 내역 : 현황별
• 개요 : 엔드포인트 현황별
• 개요 : 인종/민족별
• 등록 데이터
• 시험 시설 상위 20개국
• 세계의 상위 20 시설
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 합병, 인수, 전략적 제휴 : 지역별
• 최근 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 기업

제10장 향후 시장 촉매

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Dilated Cardiomyopathy Therapeutics.

• In 2024, more than three million diagnosed prevalent cases of DCM are anticipated in the 16 countries covered in GlobalData's epidemiology forecast.
• The treatment of DCM is primarily focused on symptom management using beta-blockers, ACE inhibitors, ARBs, MRAs, and SGLT2 inhibitors.
• Currently, 34 molecules are being developed for DCM across various stages of the pipeline.
• Over the past 10 years, the US has hosted the highest number of trial sites for DCM, at nearly 110 trial sites.
• During the past decade, acquisitions were the most prevalent deal type in North America, licensing agreements were the most common deal type in South and Central America, Africa, and Asia-Pacific.

Scope

GlobalData's Dilated Cardiomyopathy Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Dilated Cardiomyopathy Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Dilated Cardiomyopathy Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer